• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers.

作者信息

Wiedermann G, Ambrosch F, Kollaritsch H, Hofmann H, Kunz C, D'Hondt E, Delem A, André F E, Safary A, Stéphenne J

机构信息

Institute of Specific Prophylaxis and Tropical Medicine, University of Vienna, Austria.

出版信息

Vaccine. 1990 Dec;8(6):581-4. doi: 10.1016/0264-410x(90)90013-c.

DOI:10.1016/0264-410x(90)90013-c
PMID:1965077
Abstract

The reactogenicity and immunogenicity of a formaldehyde-inactivated hepatitis A vaccine have been investigated. Three different dose levels of vaccine (180, 360 and 720 ELISA units) were administered to healthy volunteers according to a 0, 1, 2 and 12 month schedule. The vaccine was safe and well tolerated. Reactions observed following vaccination were essentially mild and were not dependent upon the quantity of antigen administered. All subjects had measurable titres of anti-HAV antibodies after the full vaccination course; the immune response to the vaccine was dose-related. Antibody titres in vaccinees at month 13 were between 60- and 190-fold higher than those observed in a group of subjects given anti-HAV immunoglobulin.

摘要

相似文献

1
Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers.
Vaccine. 1990 Dec;8(6):581-4. doi: 10.1016/0264-410x(90)90013-c.
2
A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine.一项关于甲型肝炎灭活疫苗反应原性和免疫原性的试验。
Isr J Med Sci. 1994 May-Jun;30(5-6):485-8.
3
Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings.甲型肝炎灭活疫苗安全性和有效性的临床评估:基本原理与研究结果总结
Vaccine. 1992;10 Suppl 1:S160-8. doi: 10.1016/0264-410x(92)90576-6.
4
Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.三种不同批次甲型肝炎疫苗的反应原性和免疫原性
Vaccine. 1992;10 Suppl 1:S132-4. doi: 10.1016/0264-410x(92)90567-4.
5
Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.
J Med Virol. 1994 Dec;44(4):446-51. doi: 10.1002/jmv.1890440425.
6
Hepatitis A vaccination: schedule for accelerated immunization.
Vaccine. 1992;10 Suppl 1:S124-5. doi: 10.1016/0264-410x(92)90564-z.
7
Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study.
J Med Virol. 1995 Jul;46(3):287-92. doi: 10.1002/jmv.1890460321.
8
Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers.
J Gastroenterol Hepatol. 1993 Jul-Aug;8(4):338-41. doi: 10.1111/j.1440-1746.1993.tb01524.x.
9
Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals.
Vaccine. 1992;10 Suppl 1:S119-20. doi: 10.1016/0264-410x(92)90562-x.
10
Comparison of the reactogenicity and immunogenicity of two different dose levels of hepatitis A vaccine in healthy children and adolescents.两种不同剂量水平的甲型肝炎疫苗在健康儿童和青少年中的反应原性和免疫原性比较。
Asian Pac J Allergy Immunol. 1998 Jun-Sep;16(2-3):111-7.

引用本文的文献

1
Developments in Vaccine Adjuvants.疫苗佐剂的发展。
Methods Mol Biol. 2022;2412:145-178. doi: 10.1007/978-1-0716-1892-9_8.
2
Effect of rituximab on human in vivo antibody immune responses.利妥昔单抗对人体体内抗体免疫应答的影响。
J Allergy Clin Immunol. 2011 Dec;128(6):1295-1302.e5. doi: 10.1016/j.jaci.2011.08.008. Epub 2011 Sep 9.
3
Cost effectiveness of hepatitis A prevention in France.法国甲型肝炎预防的成本效益
Pharmacoeconomics. 1995 Jul;8(1):46-61. doi: 10.2165/00019053-199508010-00007.
4
Analysis of serum hepatitis A virus antibody response in different courses of hepatitis A virus infection.甲型肝炎病毒感染不同病程中血清甲型肝炎病毒抗体反应分析
J Gastroenterol. 1996 Dec;31(6):812-7. doi: 10.1007/BF02358607.
5
Clinical development of a new inactivated hepatitis A vaccine.一种新型甲型肝炎灭活疫苗的临床开发
Infection. 1996 Nov-Dec;24(6):447-58. doi: 10.1007/BF01713047.
6
Attenuated hepatitis A virus: genetic determinants of adaptation to growth in MRC-5 cells.减毒甲型肝炎病毒:适应在MRC-5细胞中生长的遗传决定因素。
J Virol. 1994 Jan;68(1):148-57. doi: 10.1128/JVI.68.1.148-157.1994.
7
Hepatitis A in Western Austria--the epidemiological situation before the introduction of active immunisation.奥地利西部的甲型肝炎——主动免疫引入前的流行病学情况。
Infection. 1994 Jan-Feb;22(1):53-5. doi: 10.1007/BF01780769.
8
Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles.重组甲型肝炎病毒14S和70S亚病毒颗粒的抗原性和免疫原性特性。
J Virol. 1993 Feb;67(2):1080-5. doi: 10.1128/JVI.67.2.1080-1085.1993.
9
The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles.由重组痘苗病毒表达的甲型肝炎病毒多聚蛋白经过蛋白水解加工并组装成病毒样颗粒。
J Virol. 1991 Sep;65(9):5029-36. doi: 10.1128/JVI.65.9.5029-5036.1991.
10
Hepatitis A.甲型肝炎
BMJ. 1991 Jun 29;302(6792):1552-3. doi: 10.1136/bmj.302.6792.1552.